^
    Back
    Association details:
    Biomarker:MYC underexpression
    Cancer:T Acute Lymphoblastic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    volasertib (NBL-001) (PLK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

    Published date:
    11/06/2019
    Excerpt:
    A higher degree of apoptosis was also observed in the combination treatment as compared to a single drug. Immunoblot analysis revealed cleavage of PARP1 and lower levels of c-Myc and MCL1 expression in the presence of both ABT-199 and BI-6727.
    DOI:
    10.1182/blood-2019-129823